)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dicot Pharma
Dicot Pharma (DICOT) investor relations material
Dicot Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
LIB-01 Phase 2b preparations progressed; initiation before year-end remains the target, with cash on hand stated to fund the planned study.
Q3 and 9M net sales were SEK 0.0m; losses reflect clinical development costs and preclinical work.
Financial highlights
Q3 operating loss was SEK 26.0m vs SEK 16.6m; loss after financial items and net loss were SEK 25.2m vs SEK 16.1m.
9M operating loss was SEK 59.7m vs SEK 65.2m; net loss was SEK 58.4m vs SEK 63.4m.
Net sales were SEK 0.0m in Q3 and 9M; other operating income was SEK 0.0m in Q3 and SEK 0.1m for 9M.
Q3 costs rose to SEK 26.1m from SEK 16.6m, mainly due to Phase 2b start-up preparations; development and other costs were SEK 23.4m vs SEK 14.5m.
Outlook and guidance
Phase 2b initiation before year-end remains the plan; FDA clearance covers the US study's first part, while EU authority decision was expected in Q4.
SEK 225.5m cash and cash equivalents were described as sufficient to conduct the planned Phase 2b study.
A parallel preclinical program is assessing LIB-01 in metabolic disease indications; research findings indicate potential beyond erectile dysfunction.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dicot Pharma
- TO 6 exercise window paired with a live Q&A and LIB-01 development overview.DICOT
Investor Update - SEK 231 million raised, phase 2b LIB-01 study set for H2 2026, cash position strengthened.DICOTQ2 2026
- Over 80% of the rights issue is secured, ensuring funding for the planned phase 2b study.DICOTInvestor update
- Phase 2b fully funded via SEK 210M rights issue; net loss narrows as LIB-01 advances.DICOTQ1 2026
- LIB-01's phase 2a success drives clinical progress, but further funding is needed for phase 2b.DICOTQ4 2025
- LIB-01's Phase 2a success and strong cash position set the stage for next clinical milestones.DICOTQ3 2025
- Phase 2a study enrollment completed; strong cash position supports next development steps.DICOTQ2 2025
- LIB-01 phase 2a trial fully funded after oversubscribed rights issue; Nasdaq listing approved.DICOTQ3 2024
- Phase 2a for LIB-01 is fully funded after a 65%-secured SEK 122.6M rights issue.DICOTQ2 2024
Next Dicot Pharma earnings date
Q4 202612 Feb, 2027
Dicot Pharma
Next Dicot Pharma earnings date
Q4 202612 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dicot AB is a pharmaceutical company focused on the development of lifestyle drugs, primarily addressing sexual health issues such as erectile dysfunction and premature ejaculation. Founded in 2021, Dicot conducts drug discovery and development aimed at improving quality of life for patients with these conditions. The company's main research involves the drug candidate LIB-01, which is in the early stages of clinical trials. Dicot AB is a private entity and maintains active operations, contributing to the healthcare and drug development sectors. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.